interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development
EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).
The EU Clinical Trials Register currently displays
44334
clinical trials with a EudraCT protocol, of which
7366
are clinical trials conducted with subjects less than 18 years old.
The register also displays information on
18700
older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see
Frequently Asked Questions ).
5 result(s) found for: CDKL5.
Displaying page 1 of 1.
EudraCT Number: 2022-001315-44
Sponsor Protocol Number: TAK-935-18-002(OV935)
Start Date*: 2022-05-24
Sponsor Name:Takeda Development Center America, Inc.
Full Title: A Multicenter, Open-label, Pilot Study of TAK-935 (OV935) in Patients With 15Q Duplication Syndrome or CDKL5 Deficiency
Disorder (ARCADE Study)
Medical condition: Epileptic Encephalopathies: Dravet Syndrome, Lennox Gastaut Syndrome, CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome
Disease:
Version
SOC Term
Classification Code
Term
Level
20.0
10010331 - Congenital, familial and genetic disorders
10073682
Dravet syndrome
LLT
20.1
10029205 - Nervous system disorders
10048816
Lennox-Gastaut syndrome
PT
22.1
10010331 - Congenital, familial and genetic disorders
10083005
CDKL5 deficiency disorder
PT
23.0
10010331 - Congenital, familial and genetic disorders
10083952
Dup15q syndrome
LLT
Population Age: Children, Adolescents, Under 18, Adults
Full Title: Adjunctive cannabidiol therapy in patients with CDKL5 deficiency disorder. Interventional drug study on efficacy and safety with focus on seizure effects
Medical condition: patients with CDKL5
Disease:
Version
SOC Term
Classification Code
Term
Level
20.0
10010331 - Congenital, familial and genetic disorders
10015039
Epilepsy congenital
PT
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults
Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EXAMINE THE EFFICACY AND SAFETY OF ZX008 IN SUBJECTS WITH CDKL5 DEFICIENCY DISORDER FOLLOWED BY AN OPEN-LABE...
Medical condition: CDKL5 DEFICIENCY DISORDER
Disease:
Version
SOC Term
Classification Code
Term
Level
22.1
10010331 - Congenital, familial and genetic disorders
10083005
CDKL5 deficiency disorder
PT
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults
Gender: Male, Female
Trial protocol:PT(Trial now transitioned)DE(Trial now transitioned)FR(Not Authorised)NL(Trial now transitioned)AT(Trial now transitioned)BE(Trial now transitioned)IE(Trial now transitioned)IT(Trial now transitioned)ES(Ongoing)
Trial results:(No results available)
EudraCT Number: 2018-001180-23
Sponsor Protocol Number: 1042-CDD-3001
Start Date*: 2018-12-06
Sponsor Name:Marinus Pharmaceuticals, Inc.
Full Title: A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed b...
Medical condition: Treatment of seizures in children and young adults with genetically confirmed cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD)
Disease:
Version
SOC Term
Classification Code
Term
Level
20.0
100000004852
10032062
Other forms of epilepsy, with intractable epilepsy
LLT
Population Age: Children, Adolescents, Under 18, Adults
Gender: Male, Female
Trial protocol:GB(GB - no longer in EU/EEA)IT(Completed)FR(Completed)PL(Completed)
Full Title: A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEP...
Medical condition: developmental and epileptic encephalopathies
Disease:
Population Age: Children, Adolescents, Under 18, Adults
Gender: Male, Female
Trial protocol:ES(Ongoing)PL(Trial now transitioned)PT(Trial now transitioned)Outside EU/EEA
Trial results:(No results available)
Subscribe to this Search
To subscribe to the RSS feed for this search click
here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options:
Number of Trials to download:
Download Content:
Download Format:
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
• EEA CTAs: Date study was authorised to proceed • Outside EU/EEA: Date study was submitted in EudraCT